阿托伐他汀早期治疗对急性冠状动脉综合征患者高敏C反应蛋白和新蝶呤的影响

目的检测不同剂量阿托伐他汀早期治疗对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hs-CRP)和新蝶呤水平变化。方法选择ACS患者60例,随机分为阿托伐他汀10 mg治疗组(A组)和阿托伐他汀40mg治疗组(B组),每组30例。同期选择冠状动脉造影正常者30例作为对照组,疗程6 d。以胶乳免疫增强比浊法和酶联免疫双抗体夹心法分别测定患者治疗前后的hs-CRP、新蝶呤水平的变化。结果与对照组比较,A组和B组患者治疗前hs-CRP、新蝶呤水平明显升高(P<0.01)。与治疗前比较,A组患者治疗后hs-CRP水平明显降低,B组患者治疗后hs-CRP和新蝶呤水平明显降低(P<0.01)。结论早期40 mg/d剂量的阿托伐他汀治疗ACS可获得较好的抗炎疗效,其抗炎稳定斑块作用独立于调脂作用。

Effect of early atorvastatin intervention on serum high sensitive C-reactive protein and neopterin in ACS patients

Objective To investigate the concentration changes of serum high sensitivety C-reactive protein(hs-CRP)and neopterin in the patients with ACS,who received early atorvastatin interventions in two different doses.Methods 60 patients with ACS were randomly and equally divided into 10 mg-atorvastatin treatment group(Group A) and 40 mg-atorvastatin treatment group (Group B),both treatments of which were lasted for 6 days.The control group consists of 30 patients with normal coronary angiography.And ELISA and immune nephelometry were applied to detect the level of plasma hs-CRP and Npt before and after treatment.Results Before atorvastatin intervention,the levels of hs-CRP and neopterin in two treatment groups were both higher than the control group(P<0.01).After 6-day treatment,hs-CRP and neopterin of Group B were significantly decreased after 6-day treatment(P<0.01) while hs-CRP of Group A were obviously decreased.Conclusion Early 40 mg-atorvastatin intervention for ACS could bring favorable antiinflammatory effects.It is not the role of lipid regulation,but plaque stabilization.